CO2020000438A2 - Anticuerpos anti-ctla-4 y sus usos - Google Patents

Anticuerpos anti-ctla-4 y sus usos

Info

Publication number
CO2020000438A2
CO2020000438A2 CONC2020/0000438A CO2020000438A CO2020000438A2 CO 2020000438 A2 CO2020000438 A2 CO 2020000438A2 CO 2020000438 A CO2020000438 A CO 2020000438A CO 2020000438 A2 CO2020000438 A2 CO 2020000438A2
Authority
CO
Colombia
Prior art keywords
antibodies
ctla
bind
lymphocytes
neutralize
Prior art date
Application number
CONC2020/0000438A
Other languages
English (en)
Inventor
Gavin Thurston
William Olson
Aynur Hermann
Ella Ioffe
Elena Burova
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of CO2020000438A2 publication Critical patent/CO2020000438A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

RESUMEN La presente invención proporciona anticuerpos que se fijan a una proteína asociada al linfocito T citotóxico 4 (CTLA-4) y métodos de uso. En distintas formas de realización de la invención, los anticuerpos son anticuerpos totalmente humanos que se fijan específicamente a CTLA-4. En algunas formas de realización, los anticuerpos de la invención son útiles para inhibir o neutralizar la actividad de CTLA-4, y así se proporciona un medio para activar linfocitos T y/o para tratar una enfermedad o un trastorno tal como cáncer o infección viral.
CONC2020/0000438A 2017-07-27 2020-01-15 Anticuerpos anti-ctla-4 y sus usos CO2020000438A2 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762537753P 2017-07-27 2017-07-27
US201762588853P 2017-11-20 2017-11-20
US201862645284P 2018-03-20 2018-03-20
US201862685599P 2018-06-15 2018-06-15
PCT/US2018/043936 WO2019023482A1 (en) 2017-07-27 2018-07-26 ANTI-CTLA-4 ANTIBODIES AND USES THEREOF

Publications (1)

Publication Number Publication Date
CO2020000438A2 true CO2020000438A2 (es) 2020-01-31

Family

ID=63165545

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2020/0000438A CO2020000438A2 (es) 2017-07-27 2020-01-15 Anticuerpos anti-ctla-4 y sus usos

Country Status (17)

Country Link
US (2) US10844137B2 (es)
EP (1) EP3658585A1 (es)
JP (2) JP7296363B2 (es)
KR (1) KR20200032189A (es)
CN (1) CN111133004B (es)
AU (1) AU2018307675A1 (es)
BR (1) BR112020001266A2 (es)
CA (1) CA3070790A1 (es)
CL (1) CL2020000216A1 (es)
CO (1) CO2020000438A2 (es)
IL (1) IL271882A (es)
MA (1) MA49687A (es)
PH (1) PH12020500078A1 (es)
SG (1) SG11202000366WA (es)
TW (1) TWI799432B (es)
WO (1) WO2019023482A1 (es)
ZA (1) ZA202000113B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017373944B2 (en) 2016-12-07 2022-02-03 Agenus Inc. Anti-CTLA-4 antibodies and methods of use thereof
TWI799432B (zh) * 2017-07-27 2023-04-21 美商再生元醫藥公司 抗ctla-4抗體及其用途
US20230071889A1 (en) 2018-12-21 2023-03-09 Ose Immunotherapeutics Bifunctional anti-pd-1/il-7 molecule
WO2020165374A1 (en) 2019-02-14 2020-08-20 Ose Immunotherapeutics Bifunctional molecule comprising il-15ra
MX2021010560A (es) * 2019-03-06 2021-11-12 Regeneron Pharma Inhibidores de la via il-4/il-13 para una eficacia aumentada en el tratamiento de cancer.
MX2022005474A (es) 2019-11-08 2022-06-02 Bristol Myers Squibb Co Tratamiento de melanoma con antagonistas del gen 3 de activacion de linfocitos (lag-3).
AU2020406083A1 (en) 2019-12-17 2022-06-16 Ose Immunotherapeutics Bifunctional molecules comprising an IL-7 variant
WO2021216920A1 (en) 2020-04-22 2021-10-28 Iovance Biotherapeutics, Inc. Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy
US20220031843A1 (en) * 2020-07-08 2022-02-03 Regeneron Pharmaceuticals, Inc. Stabilized Formulations Containing Anti-CTLA-4 Antibodies
WO2022112198A1 (en) 2020-11-24 2022-06-02 Worldwide Innovative Network Method to select the optimal immune checkpoint therapies
CN116323922A (zh) * 2020-12-17 2023-06-23 南京蓬勃生物科技有限公司 筛选靶向CD47-SIRPα免疫检查点的候选药物的方法和试剂盒
WO2022214652A1 (en) 2021-04-09 2022-10-13 Ose Immunotherapeutics Scaffold for bifunctioanl molecules comprising pd-1 or cd28 and sirp binding domains
JP2024515263A (ja) 2021-04-09 2024-04-08 オーエスイー・イミュノセラピューティクス 改善された特性を有する二機能性分子のための新規足場構造
AU2022398486A1 (en) 2021-11-24 2024-05-30 Regeneron Pharmaceuticals, Inc. Methods for treating cancer with bispecific anti-cd3 x muc16 antibodies and anti-ctla-4 antibodies
WO2023201369A1 (en) 2022-04-15 2023-10-19 Iovance Biotherapeutics, Inc. Til expansion processes using specific cytokine combinations and/or akti treatment
WO2024003360A1 (en) 2022-07-01 2024-01-04 Institut Curie Biomarkers and uses thereof for the treatment of neuroblastoma
WO2024028386A1 (en) 2022-08-02 2024-02-08 Ose Immunotherapeutics Multifunctional molecule directed against cd28
WO2024112571A2 (en) 2022-11-21 2024-05-30 Iovance Biotherapeutics, Inc. Two-dimensional processes for the expansion of tumor infiltrating lymphocytes and therapies therefrom

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7109003B2 (en) 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
RS51309B (sr) 1998-12-23 2010-12-31 Pfizer Inc. Humana monoklonalna antitela za ctla-4
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
CN1371416B (zh) 1999-08-24 2012-10-10 梅达里克斯公司 人ctla-4抗体及其应用
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
US7850962B2 (en) 2004-04-20 2010-12-14 Genmab A/S Human monoclonal antibodies against CD20
US8257740B1 (en) 2011-08-15 2012-09-04 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
US8246995B2 (en) 2005-05-10 2012-08-21 The Board Of Trustees Of The Leland Stanford Junior University Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells
US7582298B2 (en) 2006-06-02 2009-09-01 Regeneron Pharmaceuticals, Inc. High affinity antibodies to human IL-6 receptor
EP2240204A1 (en) * 2008-02-04 2010-10-20 Medarex, Inc. Anti-clta-4 antibodies with reduced blocking of binding of ctla-4 to b7 and uses thereof
RU2522002C2 (ru) 2009-06-26 2014-07-10 Ридженерон Фармасьютикалз, Инк. Легковыделяемые биспецифические антитела с природным иммуноглобулиновым форматом
GB201103955D0 (en) 2011-03-09 2011-04-20 Antitope Ltd Antibodies
TWI635098B (zh) 2013-02-01 2018-09-11 再生元醫藥公司 含嵌合恆定區之抗體
TWI680138B (zh) * 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
CA2940685C (en) * 2014-03-11 2023-10-24 Regeneron Pharmaceuticals, Inc. Anti-egfrviii antibodies and uses thereof
TWI754319B (zh) * 2014-03-19 2022-02-01 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
ES2882157T3 (es) * 2015-02-13 2021-12-01 Sorrento Therapeutics Inc Productos terapéuticos de anticuerpos que se unen a CTLA4
EP3303394B1 (en) * 2015-05-29 2020-04-08 Agenus Inc. Anti-ctla-4 antibodies and methods of use thereof
US11208483B2 (en) 2015-11-19 2021-12-28 Shanghai Kanda Biotechnology Co, Ltd. CTLA-4 antibodies and uses thereof
CN110168105B (zh) 2016-12-09 2024-05-24 瑞泽恩制药公司 用于对t细胞受体进行测序的系统和方法及其用途
TWI799432B (zh) * 2017-07-27 2023-04-21 美商再生元醫藥公司 抗ctla-4抗體及其用途

Also Published As

Publication number Publication date
ZA202000113B (en) 2021-07-28
JP2023113893A (ja) 2023-08-16
US20210040232A1 (en) 2021-02-11
CN111133004A (zh) 2020-05-08
SG11202000366WA (en) 2020-02-27
IL271882A (en) 2020-02-27
US20190048096A1 (en) 2019-02-14
WO2019023482A1 (en) 2019-01-31
CN111133004B (zh) 2023-12-01
KR20200032189A (ko) 2020-03-25
JP7296363B2 (ja) 2023-06-22
EP3658585A1 (en) 2020-06-03
JP2020528750A (ja) 2020-10-01
BR112020001266A2 (pt) 2020-07-28
CL2020000216A1 (es) 2020-07-10
AU2018307675A1 (en) 2020-02-20
TW201920267A (zh) 2019-06-01
US10844137B2 (en) 2020-11-24
MA49687A (fr) 2020-06-03
TWI799432B (zh) 2023-04-21
PH12020500078A1 (en) 2020-11-09
CA3070790A1 (en) 2019-01-31

Similar Documents

Publication Publication Date Title
CO2020000438A2 (es) Anticuerpos anti-ctla-4 y sus usos
CO2018003738A2 (es) Anticuerpos anti-lag3 y sus usos
CL2018003563A1 (es) Anticuerpos anti-c5 y usos de los mismos.
AR116718A1 (es) Proteínas de unión triespecíficas anti-cd38, anti-cd28 y anti-cd3 y métodos de uso para tratar infección vírica
CY1124771T1 (el) Αντισωματα εναντι-σορτιλiνης και μεθοδοι χρησης αυτων
CL2017003261A1 (es) Factor xi anticuerpos y métodos de uso
CY1123977T1 (el) Anti-pd-1 και anti-lag3 αντισωματα για την θεραπεια του καρκινου
CL2022003763A1 (es) Anticuerpos humanos contra glicoproteína del virus ébola
CY1124747T1 (el) Ανθρωπινα αντισωματα σε pd-1
CL2018003583A1 (es) Anticuerpos anti-pd-l1 y usos de los mismos.
CO2019011155A2 (es) Anticuerpos anti-ilt4 y fragmentos de unión a antígeno
CL2018000744A1 (es) Anticuerpos anti-tigit (inmunoreceptor de linfocitos t con dominios ig e itim) y metodos de uso.
ECSP18045028A (es) Anticuerpos neutralizadores del virus de inmunodeficiencia humana
ECSP20082648A (es) Anticuerpos anti-sirpa y métodos de utilización de los mismos
UY36539A (es) Proteínas de unión a icos
CR20180105A (es) Diacuerpos monovalentes biespecificos que son capaces de unirse a b7-h3 y cd3, y usos de los mismos
PE20160690A1 (es) Anticuerpos anti-cd134 (ox40) humanizados y usos de los mismos
PA8794201A1 (es) Anticuerpos anti-cxcr5 humanizados, derivados de los mismos y su uso
CO2020013089A2 (es) Anticuerpos contra mica y/o micb y sus usos
AR114284A1 (es) Moléculas de unión a antígeno dirigidas a her2 que comprenden 4-1bbl
EA202090204A1 (ru) Анти-cd137 антитела
CL2023001377A1 (es) Anticuerpos anti-npr1 y usos de los mismos
CL2019002953A1 (es) Anticuerpo anti-pd-l1 y uso del mismo.
BR112019005944A2 (pt) anticorpos que se ligam à interleucina 2 e usos dos mesmos
CY1122072T1 (el) Μη-ανταγωνιστικα αντισωματα κατευθυνομενα εναντι της αλφα αλυσου του εξωκυτταρικου πεδιου υποδοχεα il7 και χρηση αυτων σε θεραπεια καρκινου